![In a Major Shift, Cancer Drugs Go ‘Tissue-Agnostic’](/summary-img/31224-JOIDVODS.jpg?h=M&b=0)
Article
In a Major Shift, Cancer Drugs Go ‘Tissue-Agnostic’
Encouraged by an FDA approval, companies design cancer drugs to work in any solid tumor
Science,
2017
Recommendation
Ken Garber reports on a breakthrough in the treatment of cancer. He explains so-called “tissue-agnostic” drugs in thorough detail, proving his longstanding experience as a science writer. He uses complex medical terms to discuss biomedical mechanisms and drug development. However, he manages to break down the essential information for a general audience. getAbstract recommends this article to anyone interested in new developments in cancer treatment.
Summary
About the Author
Ken Garber is a science writer in Ann Arbor, Michigan with longstanding experience covering biology and medicine. He has written for Science, Nature, Nature Biotechnology and Nature Medicine. He is also a contributing correspondent for the Journal of the National Cancer Institute.
Comment on this summary or Diskussion beginnen